Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
TimesSquare Capital Management U.S. Small Cap Growth Strategy TimesSquare Capital Management, LLC | “New to the strategy was Axogen, Inc., which develops technologies for peripheral nerve regeneration and repair from injuries caused by trauma, chronic conditions, or surgical procedures. Its flagship product, Avance Nerve Graft, is a decellularized human nerve allograft that preserves native nerve microarchitecture while eliminating immune rejection risk. It is the only FDA-approved implantable biological nerve allograft on the market. BSD Analysis: Axogen operates in nerve repair, a niche medtech category with real unmet clinical need. Outcomes matter more than procedure volume, which supports long-term adoption if data holds. Surgeon education and reimbursement are the gating factors, not awareness. Revenue growth has been uneven, testing investor patience. Cash burn and capital access remain real risks. Yet first-mover advantage and clinical specialization create defensibility. If utilization scales, operating leverage is substantial. This is medtech execution risk, not a science problem.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Axogen, Inc. is a leader in technologies focused on peripheral nerve regeneration and repair. The company's biologically active nerve graft platform reduces procedural risk by eliminating the need for secondary surgical sites. Shares advanced during the quarter following accelerated revenue growth of 20% and gross margins approaching 77%, exceeding investor expectations. Favorable reimbursement terms were secured, supporting broader hospital adoption. Additionally, FDA approval of a BLA submission without restrictive labeling granted 12 years of market exclusivity. BSD Analysis: Axogen operates in nerve repair, a niche medtech category with real unmet clinical need and limited direct competition. Clinical outcomes and surgeon training matter more than marketing spend, which slows adoption but strengthens long-term stickiness. Revenue growth has been uneven, testing investor patience and credibility. Cash burn and capital access remain real overhangs. That said, first-mover advantage and expanding clinical data support relevance. If utilization scales across trauma and surgical repair, operating leverage is substantial. This is not a gadget story — it's procedural adoption risk. Execution, not science, decides the outcome.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Meridian Small Cap Growth Fund Chad Meade | “Axogen, Inc. is a leader in the development of technologies focused on peripheral nerve regeneration and repair. The company's biologically active nerve graft platform reduces procedural risks by eliminating the need for secondary surgical sites. During the quarter, Axogen reported top-line growth of 17% and reaffirmed its full-year guidance for both revenue growth and gross margin. Despite this positive momentum, shares declined following a weaker-than-expected Q1 gross margin of 72%, which came in below the company's guided range of 73–75%. The shortfall was attributed to a one-time inventory adjustment and ongoing manufacturing transition. We believe the ramp-up of Axogen's new manufacturing facility positions the company for long-term margin expansion, with the potential to exceed 80% gross margins. Given our conviction in the operational improvement expected in the second half of the year, we added to our position during the period. BSD Analysis: Axogen is positioned for multi-year margin expansion as its new facility scales and manufacturing transitions normalize. Strong double-digit revenue growth reflects rising adoption of nerve regeneration solutions with high clinical differentiation. Shares trade at a discount to long-term growth potential, with catalysts including gross margin recovery, broader surgeon adoption, and potential CMS reimbursement updates.” | BULL | Q2 2025 Jun 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
